LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

Home・Aktien・CytoSorbents Corp

CytoSorbents Corp

Geschlossen

BrancheGesundheitswesen

0.56 -8.2

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

0.56

Max

0.61

Schlüsselkennzahlen
By Trading Economics
Einkommen	-2.3M -5.5M
Verkäufe	-251K 9.2M
Gewinnspanne	-59.526
Angestellte	129
EBITDA	-766K -3.7M

Empfehlungen
By TipRanks
Empfehlungen	Neutral
12-Monats-Prognose	+22.95% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	13. Mai 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-3.4M 39M
Vorheriger Eröffnungskurs	8.76
Vorheriger Schlusskurs	0.56

Nachrichtenstimmung

By Acuity

93%

337 / 346 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

0.705 / 0.771 Unterstützung & Widerstand

CytoSorbents Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

CytoSorbents Corp Prognose

Kursziel

By TipRanks

22.95% Vorteil

12-Monats-Prognose

Durchschnitt 0.75 USD 22.95%

Hoch 0.75 USD

Tief 0.75 USD

Basierend auf 1 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für CytoSorbents Corp – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

1 ratings

Buy

Halten

Sell

Basierend auf 1 Analysten, die in den letzten 3 Monaten Aktienbewertungen für CytoSorbents Corp – Dist abgegeben haben.

Technischer Score

By Trading Central

0.705 / 0.771Unterstützung & Widerstand

All events are bearish.

Stimmung

By Acuity

337 / 346 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über CytoSorbents Corp

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.